Comparative efficacy and safety of anti-PD-1 therapies used in metastatic colorectal cancer: a systematic review and network meta-analysis
Main Article Content
Keywords
metastatic colorectal cancer, microsatellite instability, pembrolizumab, nivolumab
Abstract
Objective: Systemic studies on anti-PD-1 therapy in patients with metastatic colorectal cancer (mCRC) with microsatellite instability or mismatch repair defects are lacking. We aimed to summarize the evidence regarding the efficacy and safety of pembrolizumab, nivolumab, ipilimumab, and tislelizumab in mCRC. Methods: Network meta-analyses (NMAs) can provide comparative efficacy and safety data for clinical decision-making. In this NMA, eligible publications from PubMed, EMBASE, Web of Science, and Cochrane Library from 2016 to April 2023 were identified through a systematic literature review. Literature screening and data extraction were performed according to established criteria. The quality of the literature was evaluated using the Cochrane risk of bias tool, and statistical analysis was performed using Revman5.4 and R language. The main outcome indicators, DCR, ORR, PFS, and OS, were used to evaluate the effectiveness of the drugs, and the main outcome indicators AE and SAE were used to evaluate the safety of each program. Results: Fifteen studies with a sample size of 798 patients were included. In terms of effectiveness, the disease control rate DCR of PD-1 inhibitors was 0.727[95% CI:0.654-0.794]; objective response rate ORR was 0.448[95% CI:0.382-0.514]; and the 1-year progression-free survival rate was 0.551[95% CI:0.458-0.642]. The 1-year overall survival rate was 0.790[95% CI:0.705-0.865]. The adverse events associated with anti-PD-1 were 0.567[95% CI:0.344-0.778] in terms of safety. The total incidence of grade 3 or higher adverse events was 0.241[95% CI:0.174-0.313]. In the subgroup analysis results, the incidence of DCR in the nivolumab + ipilimumab group was 0.826[95% CI:0.780-0.869], the ORR was 0.512[95% CI:0.377-0.647], and the PFS was 0.668[95% CI:0.516-0.804]. The incidence of AE was 0.319 [95% CI:0.039-0.700] and SAE was 0.294 [95% CI:0.171-0.433]. Conclusions: The efficacy of nivolumab + ipilimumab was superior to that of pembrolizumab and nivolumab, with a low incidence of side effects and controllable safety..
References
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for36 cancers in 185 countries [J]. A Cancer Journal for Clinicians.2021;71(3):209-249. https://doi.org/10.3322/caac.21660
3. Sinicrope FA, Sargent DJ. Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications [J]. Clin Cancer Res an Off J Am Assoc Cancer Res. 2012; 18(6):1506–1512. https://doi. org/10.1158/1078-0432.ccr-11-1469
4. Lin A, Zhang J, Luo P. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Front Immunol. 2020;11:2039. https://doi.org/10.3389/fimmu.2020.02039
5. Boukouris AE, Theochari M, Stefanou D, et al. Latest evidence on immunecheckpoint inhibitors in metastatic colorectal cancer: A 2022 update[J]. Critical Reviews in Oncology/Hematology. 2022;173(5):103663. https://doi.org/10.1016/j. critrevonc.2022.103663
6. Fan A, Wang B, Wang X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective[J]. Int J Biol Sci. 202;17(14): 3837-3849. https://doi.org/10.7150/ijbs.64077
7. Casak SJ, Marcus L, Fashoyin-Aje L, et al. FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma. Clin Cancer Res. 2021; 27(17):4680-4684. https:// doi.org/10.1158/1078-0432.CCR-21-0557
8. Kishore C, Bhadra P. Current advancements and future perspectives of immunotherapy in colorectal cancer research. Eur J Pharmacol. 2021;893:173819. https://doi.org/10.1016/j.ejphar.2020.173819
9. Wang C, Fakih M. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner? Expert Opin Biol Ther. 2021;21(10):1347-1357. https://doi.org/10.1080/14712598.2021.1933940
10. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science. 2017;357(6349):409-413. https://doi.org/10.1126/science.aan6733
11. Marcus L, Lemery SJ, Keegan P, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability- High Solid Tumors[J]. Pazdur Richard Clinical cancer research. 2019;25(13):3753-3758. https://doi.org/10.1158/1078-0432. ccr-18-4070
12. Sinicrope FA, Chakrabarti S, Eiring R, et al. Clinical outcome of patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with pembrolizumab[J]. Journal of Clinical Oncology. 2018;36(15):24127.
13. Kawazoe A, Kuboki Y, Shinozaki E, et al. Multicenter phase I/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial)[J]. Clinical Cancer Research. 2020;26(22):5887-5894. https://doi. org/10.1158/1078-0432.ccr-20-1803
14. André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207-2218. https://doi.org/10.1056/nejmoa2017699
15. Kuang C, Park Y, Bahary N, et al. Biomarker analysis for UPCI 14- 118: Phase II study of pembrolizumab in combination with azacitidine in patients with refractory metastatic colorectal cancer[J]. Journal of Clinical Oncology. 2020;38(4):173-173.
16. Yoshino T, Kim TW, Yong WP, et al. PS1-2 Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: Asia subgroup of phase 3 KEYNOTE-177[J]. Annals of Oncology. 2021;32(4):284.
17. Ghaus A, Pheely A, Murdock V, et al. Real-world experience of pembrolizumab in microsatellite instability-high CRC: A Scottish multicenter analysis[J]. Journal of Clinical Oncology. 2022;40(4):54-5
18. Leal AD, Paludo J, Finnes HD, et al. Response to pembrolizumab in patients with mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)[J]. Journal of Clinical Oncology. 2017;35(4):714-714.
19. Omar NEH, Nasser S, Gasim M, et al. Safety of immune checkpoint inhibitors in cancer patients with microsatellite instabilityhigh (MSI-H) status: An experience from Qatar[J]. JNCCN Journal ofthe National Comprehensive Cancer Network. 2019;17(3- 5):45-45.
20. Le DT, Kim TW, Van CE, et al. Phase II Open-Label Studyof Pembrolizumab in Treatment-Refractory, Microsatellite Instability- High/Mismatch Repair-Deficient MetastaticColorectal Cancer: KEYNOTE-164[J]. Journal of clinical oncology. 2020;38(1):11-19.
21. Bergamo F, Overman MJ, McDermott RS, et al. Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142[J]. Journal of Clinical Oncology. 2018;36(4):554-555.
22. Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient Metastatic Colorectal Cancer: the Phase II CheckMate 142 Study[J]. Journal of clinical oncology. 2021;40(2):161-170. https://doi.org/10.1200/jco.21.01015
23. Cohen R, Meurisse A, Pudlarz T, et al. One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study[J]. Journal of Clinical Oncology. 2022;40(4):13. https://doi.org/10.1136/jitc-2020-001499
24. André T, Lonardi S, Wong KYM, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142[J]. Annals of Oncology. 2022;33(10):1052-1060. https://doi.org/10.1016/j.annonc.2022.06.008
25. Lam JJM, Bridgewater J, Alani M, et al. Nivolumab, alone or with ipilimumab, for mismatch repair deficient metastatic colorectal cancer: A United Kingdom multicentre analysis of patient outcomes[J]. Annals of Oncology. 2020;40(2):161-170.
26. Andre T, Lonardi S, Wong KYM, et al. Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study[J]. Journal of Clinical Oncology. 2017;35(15):3531-3531.
27. Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928
28. Wang FH, Zhang XT, Li YF, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021[J].Cancer Commun (Lond). 2021;41(8):747-795. https://doi.org/10.1002/cac2.12193
29. Huynh JC, Schwab E, Kim E, et al. Recent advances in targeted therapies foradvanced gastrointestinal malignancies[J]. Cancers. 2020;12(5):1168. https://doi.org/10.3390/cancers12051168
30. Cho BC, Lee KH, Ahn MJ, et al. 474O - Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC [J].Annals of Oncology. 2019;30(9):157-158.
31. Buchroithner J, Pichler J, Marosi C, et al. Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy. Int J Clin Pharmacol Ther. 2014;52(1):76-7. https://doi.org/10.5414/CPXCES13EA02
32. hiu KK, Diaz LA, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repairdeficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label,phase 3 study[J]. Lancet Oncol. 2022;23(5):659-670. https://doi.org/10.1016/s1470-2045(22)00197-8
33. Fukuoka S, Hara H, Takahashi N, et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38(18):2053- 2061. https://doi.org/10.1200/JCO.19.03296
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.